Merck and Moderna reported that INTerpath-001 met its recurrence-free-survival primary endpoint and a key distant-metastasis-free-survival endpoint. Their August 19, 2026 announcement concerns intismeran autogene plus Keytruda after complete removal of melanoma. It does not disclose the Phase 3 hazard ratios or absolute event counts. 1
That missing numerical detail matters. A positive topline announcement can be meaningful without supporting a precise percentage-benefit headline.
Intismeran, V940 and mRNA-4157 are names for the same program
Intismeran autogene is the individualized neoantigen therapy also identified as V940 or mRNA-4157. Keytruda is pembrolizumab, the checkpoint inhibitor used in the combination. INTerpath-001 is the Phase 3 study; KEYNOTE-942 is the earlier Phase 2b study. 1 2
Keeping the product name and trial name in separate fields prevents two errors: counting one program several times under different names, and transferring a result from one trial to another.
What the Phase 3 study compared
The sponsor describes INTerpath-001, NCT05933577, as a randomized, double-blind trial involving 1,137 people with completely resected stage IIB–IV cutaneous melanoma. Participants were assigned 2:1 to the combination or its pembrolizumab comparator. Overall-survival follow-up continues. 1
This is not a comparison with receiving no cancer care. The interpretive question is what adding the individualized therapy changes relative to the comparison regimen.
Because participants entered a postsurgical setting, the primary question also differs from whether a vaccine makes an untreated visible tumor disappear. Read an adjuvant result in the clinical situation actually studied.
What can be said now—and what cannot
| Question | Supported answer from the August announcement |
|---|---|
| Did the sponsor announce success on the specified endpoints? | Yes, for recurrence-free survival and the named distant-metastasis endpoint |
| What is the numerical Phase 3 effect size? | Not supplied in that announcement |
| What proportion remained recurrence-free at a chosen time? | A complete Phase 3 estimate is not provided there |
| Did it demonstrate an overall-survival benefit? | The announcement says follow-up for that endpoint continues |
| Is there a full Phase 3 safety table? | Not in the source used for this report |
The table summarizes the source’s scope, not a forecast of what the eventual detailed analysis will show. 1
Do not move the 49% figure into Phase 3
The announcement also discusses five-year Phase 2b follow-up and gives a 49% relative reduction in recurrence or death for that earlier analysis. That background number is not the disclosed effect size from INTerpath-001. 3
The error is easy to make: a document has “Phase 3” in its headline and a percentage several paragraphs below. The percentage still belongs to the study identified in its own paragraph.
The KEYNOTE-942 explainer keeps the earlier published analysis separate. Different follow-up dates can also produce different estimates within the same trial; that is a reason to label the data cut, not automatically evidence of contradiction.
Benefit and harm need matched denominators
The companies reported no new safety signals in the Phase 3 announcement. That is not equivalent to no adverse events, and it is not a substitute for counts of serious events, discontinuations and treatment-related events by randomized group. 1
For the complete assessment, efficacy and safety should concern the same regimen and relevant trial population. A long package-insert safety section about pembrolizumab in other cancers cannot be substituted for this trial’s comparative safety results.
NCI explains that checkpoint inhibitors can produce immune-related adverse effects; adding a biologically plausible vaccine does not eliminate the need to evaluate the combination. 4
Is intismeran approved or on sale?
The August source calls intismeran investigational and describes plans for regulatory engagement. It does not establish approval, a release date, price or ordinary clinical availability. 1
The appropriate status for this report is positive sponsor-reported Phase 3 topline findings; detailed results and regulatory outcomes not established here. Do not pay an intermediary on the assumption that a media report proves access to the studied product.
For the broader field, see cancer vaccine research. For study records and access boundaries, use the clinical-trial guide. This page reports a program milestone, not personal eligibility or a recommendation to alter treatment.